CytomX Therapeutics

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytomX Therapeutics reports robust financials and strategic pipeline advancements

CytomX Therapeutics showcased strong financial performance, with a focus on advancing key therapeutic programs and collaborations with industry partners. The company's strategic capital allocation supports pipeline development, while challenges include program prioritization and industry competition. Opportunities for growth exist in advancing pipeline milestones and leveraging collaborations for innovation.

CytomX reports robust Q1 earnings, advances pipeline with key partners

CytomX Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2023
The company's strategic collaborations and focus on innovation position it for future growth
Balancing expenses, regulatory milestones, and clinical progress are key challenges and opportunities
Overall, CytomX is well-positioned to drive value through its transformative therapies

CytomX advances pipeline and partnerships, poised for growth in oncology

CytomX Therapeutics demonstrated strong performance, financial stability, and strategic partnerships in Q2 2023, signaling a promising outlook for future growth.
The company's focus on localized therapies, leadership team strength, and diverse pipeline underscore its competitive position in the biopharmaceutical industry.
While facing challenges in a competitive landscape, CytomX has opportunities for growth through innovative programs, partnerships, and alignment with industry trends.

CytomX Therapeutics reports strong Q3 earnings and outlines strategic roadmap

CytomX Therapeutics showcased solid financial performance in Q3 2023 with revenue of $26.4 million and prudent cost management.
The company's focus on cancer medicines and pipeline advancements position it well for future growth and market competitiveness.
While facing challenges in data updates and cost balancing, strategic milestones and opportunities for collaborations offer avenues for expansion.
Overall, CytomX Therapeutics remains well-positioned in the oncology sector with a strong cash position and promising pipeline candidates.

CytomX posts robust Q4 results, poised for growth in 2024

CytomX Therapeutics delivered a strong performance in Q4 2023, showcasing financial stability, progress on its Probody platform, and strategic partnerships to drive innovation.
While facing challenges in clinical development and partnership dynamics, the company's strengths in product pipeline diversity and financial management offer a solid foundation for future growth.
With exciting opportunities ahead, including upcoming data readouts and advancements in immunotherapy, CytomX is well-positioned to capitalize on its expertise in antibody masking and conditional activation.

CytomX reports positive Phase Ia data for CX-904 therapy

CytomX Therapeutics showcases strong performance with promising drug data.
Company's financial stability and innovative platform position it well for growth.
Challenges in translating research to clinical outcomes and predicting patient responses.
Opportunities lie in expanding drug potential, exploring combination strategies, and addressing assay challenges.

CytomX reports strong Q3 results, advances promising oncology therapies

CytomX Therapeutics delivered solid financial performance in Q3 2024 with a focus on key oncology programs.
The company's Probody platform shows promise in addressing unmet medical needs in various cancers.
Challenges lie in optimizing dose escalation, enrollment, and expansion of therapies to maximize impact.
Strategic partnerships and disciplined capital allocation position CytomX for future growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Slumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma

Allogene Therapeutics Inc

Amgen

Arvinas Inc

MacroGenics

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe.

5 ASCO Abstracts Moving Biopharma Stocks

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q1 2020 Results - Earnings Call Transcript

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

SOUTH SAN FRANCISCO, Calif., April  28, 2020  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the appointment of Halley E. Gilbert to the company’s board of directors. Ms. Gilbert brings to CytomX extensive leadership experience in the biopharmaceutical industry, with particular expertise in corporate and business development, legal, compliance and corporate strategy.  

CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors

CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why CytomX Therapeutics (CTMX) Stock Might be a Great Pick

Does CytomX Therapeutics (CTMX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why CytomX Therapeutics (CTMX) is a Great Momentum Stock to Buy

AudioEye Inc

Chembio Diagnostics

Manning & Napier

Top Ranked Momentum Stocks to Buy for April 17th

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's What You Should Know

As of late, it has definitely been a great time to be an investor CytomX Therapeutics

Will CytomX Therapeutics Continue to Surge Higher?

Aytu BioScience

DHT Holdings

ElectroCore Inc

Top Ranked Momentum Stocks to Buy for April 3rd

Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payment to CytomX

CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline

CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.

CytomX & Astellas Collaborate to Develop Novel Cancer Therapy

      - Collaboration to Utilize CytomX’s Novel Probody® Technology Platform  for CD3 Bispecific Targets -       -  CytomX to Receive $80 Million Upfront Payment and       Ability to Exercise Option for U.S. Co-Commercialization Rights -

CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody®  T-Cell Engaging Bispecific Therapies for Treatment of Cancer

SOUTH SAN FRANCISCO, Calif., March  23, 2020  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the appointment of Carlos Campoy as senior vice president and chief financial officer.

CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER

SOUTH SAN FRANCISCO, Calif., March  16, 2020  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that on March 2, 2020, the Company granted two new employees options to purchase a total of 70,000 shares of the Company’s common stock at an exercise price per share equal to $3.61, which was the closing trading price on March 16, 2020, the date of the grant.

CytomX Therapeutics Announces  New Employment Inducement Grant

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2019 Results - Earnings Call Transcript

Expansion Phase to Evaluate CTLA-4-Directed Probody®   Therapeutic in Combination with Opdivo® in Metastatic Melanoma 

Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will CytomX Therapeutics (CTMX) Report Negative Q4 Earnings? What You Should Know

SOUTH SAN FRANCISCO, Calif., Feb.  07, 2020  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that on February 3, 2020, the Company granted its recently appointed senior vice president and chief medical officer, Alison L. Hannah, M.D., an option to purchase 250,000 shares of the Company’s common stock at an exercise price per share equal to $7.71, which was the closing trading price on February 3, 2020, the date of the grant. The Company also granted Dr. Hannah a performance option to purchase 50,000 shares of the Company’s common stock at an exercise price per share equal to $7.71.

CytomX Therapeutics  Announces  New Employment Inducement Grant

SOUTH SAN FRANCISCO, Calif., Feb.  03, 2020  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the appointment of Alison L. Hannah, M.D., as senior vice president and chief medical officer.

CytomX Therapeutics Appoints Alison L. Hannah, M.D.

  - Wholly-Owned anti-PD-L1 and anti-CD166 Programs Entering Phase 2 Studies –

CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook

SOUTH SAN FRANCISCO, Calif., Dec.  17, 2019  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that on December 16, 2019, the Company granted six new employees options to purchase a total of 36,800 shares of the Company’s common stock at an exercise price per share equal to  $7.26, which was the closing trading price on December 16, 2019, the date of the grant. 

CytomX Therapeutics Announces New Employment Inducement Grants.

CytomX Therapeutics Inc (NASDAQ: CTMX) reported disappointing third-quarter results and lacks clarity into the path forward for its wholly-owned PD-L1 Probody CX-072, according to Wedbush.

Wedbush Downgrades CytomX Due To Lack Of Clarity On Development Paths

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2019 Results - Earnings Call Transcript

News for CytomX Therapeutics Stock (CTMX)